Evidence map›Paper›PMID 42656289›Full record

ArticleFrontiers in medicine2026

Novel

Rong Tao, Ten Zhang, Fangmei Luo, Yihui Liu, Liangliang Fan, Xuan Wu, Yuxing Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rong Tao *Center for Medical Research, Pingshan District Central Hospital of Shenzhen, Shenzhen, Guangdong, China.
Ten Zhang *Department of Neurology, Affiliated Hospital of Yangzhou University, Yangzhou, China.
Fangmei LuoDepartment of Cell Biology, The School of Life Sciences, Central South University, Changsha, China.
Yihui LiuDepartment of Neurology, Affiliated Hospital of Yangzhou University, Yangzhou, China.
Liangliang FanDepartment of Cell Biology, The School of Life Sciences, Central South University, Changsha, China.
Xuan WuDepartment of Neurology, Affiliated Hospital of Yangzhou University, Yangzhou, China.
Yuxing LiuLaboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated Hospital of Guilin Medical University, Guilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Charcot-Marie-Tooth disease type 2Z (CMT2Z) is an uncommon inherited condition characterized by autosomal dominant inheritance. It is marked by axonal neuropathy, leading to progressive muscle weakness, cramps, and sensory loss. Methods: Here, we enrolled two families affected by Charcot-Marie-Tooth (CMT) disease, with both families having probands who exhibit distal lower limb weakness. Whole-exome sequencing (WES) was used to explore the genetic lesion. Results: Two heterozygous variants (NM_001303256, c.34G > C;p.A12P; NM_001303256, c.848G > A;p.R283H) of Conclusion: Our research contributed to the genetic assessment and guidance for these families, reinforcing the notion that

Indexed as

axonal neuropathyCMT2ZMORC2variantWES

Identifiers

PMID42656289
PMCPMC13506280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.